Tau phosphorylation, molecular chaperones, and ubiquitin E3 Ligase: Clinical relevance in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 2, 2015, Pages 341-361

  Kumar, Pravir ^a,b,c   Jha, Niraj Kumar ^a   Jha, Saurabh Kumar ^a   Ramani, Karunya ^b   Ambasta, Rashmi K ^a,b  

^a DELHI TECHNOLOGICAL UNIVERSITY   (India)

^b VIT UNIVERSITY   (India)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heat shock proteins; tau phosphorylation; tauopathy; ubiquitin E3 ligase

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; PHOSPHOTRANSFERASE; TAU PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE;

ALZHEIMER DISEASE; HUMAN; NEUROPATHOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; ANIMAL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MOLECULAR CHAPERONES; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES; UBIQUITIN-PROTEIN LIGASES;

EID: 84911879504     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140933     Document Type: Review

References (197)

1. Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D (2011) AMP-activated protein kinase (AMPK) is a taukinase, activated in response to amyloid-peptide exposure. Biochem J 434, 503-512.
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimercyto skeletal pathology. Proc Natl Acad Sci USA 83, 4913-4917.
3. Lee VM, Balin BJ, Otvos L, Jr. , Trojanowski JQ (1991) A68:A major subunit of paired helical filaments and derivatizedforms of normal tau. Science 251, 675-678.
4. Matsuo ES, Shin RW, Billingsley ML, Van de Voorde A, O'Connor M, Trojanowski JQ, Lee VM (1994) Biopsyderivedadult human brain tau is phosphorylated at many ofthe same sites as Alzheimer's disease paired helical filamenttau. Neuron 13, 989-1002.
5. Mandelkow EM, Biernat J, Drewes G, Gustke N, Trinczek B, Mandelkow E (1995) Tau domains, phosphorylation, andinteractions with microtubules. Neurobiol Aging 16, 355-362.
6. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core proteinin Alzheimer disease and Down syndrome. Proc Natl AcadSci USA 82, 4245-4249.
7. Selkoe DJ (1994) Normal and abnormal biology of the betaamyloid precursor protein. Annu Rev Neurosci 17, 489-517.
8. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurode generation in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
9. Nijholt DA, van Haastert ES, Rozemuller AJ, Scheper W, Hoozemans JJ (2012) The unfolded protein response isassociated with early tau pathology in the hippocampus of tauopathies. J Pathol 226, 693-702.
10. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, Ihara Y (1995) Proline-directedand non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270, 823-829.
11. Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, Litersky JM, Schenk D, Liberberg I, Trojanowski JQ, Lee V. M.-Y. (1995) Detection of phosphorylated Ser 262 in fetal tau, adult tau, and paired helicalfilament tau. J Biol Chem 270, 18917-18922.
12. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, AndertonBH (2007) Novel phosphorylation sites in tau from Alzheimer brainsupport a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282, 23645-23654.
13. Fu H, Subramanian RR, Masters SC, Fu H, Subramanian RR, Masters SC (2000) 14-3-3 proteins: Structure, function, and regulation. Annu Rev Pharmacol Toxicol 40, 617-647.
14. Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in thenervous system. Nat Rev Neurosci 4, 752-762.
15. Heah PS, Ramshaw HS, Thomas PQ, Toyo-Oka K, Xu X, Martin S, Coyle P, Guthridge MA, Stomski F, van den Buuse M, Wynshaw-Boris A, Lopez AF, Schwarz QP (2012) Neuro developmental and neuropsychiatric behaviour defectsarise from 14-3-3zeta deficiency. Mol Psychiatry 17, 451-466.
16. Ramser EM, Wolters G, Dityateva G, Dityatev A, Schachner M, Tilling T (2010) The 14-3-3zeta protein binds to thecell adhesion molecule L1, promotes L1 phosphorylationby CKII and influences L1-dependent neurite outgrowth. PLoS One 5, e13462.
17. Soulié C, Nicole A, Delacourte A, Ceballos-Picot I (2004) Examination of stress-related genes in human temporal versusoccipital cortex in the course of neurodegeneration:Involvement of 14-3-3 zeta in this dynamic process. NeurosciLett 365, 1-5.
18. Leugers CJ, Lee G (2010) Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signalingand neurite initiation without a requirement for microtubulebinding. J Biol Chem 285, 19125-19134.
19. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM (2001) PP2A mRNA expression is quantitatively decreasedin Alzheimer's disease hippocampus. Exp Neurol 168, 402-412.
20. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL 3rd (2004) Altered expression levels ofthe protein phosphatase 2A AB alphaC enzyme are associatedwith Alzheimer disease pathology. J Neuropathol Exp Neurol 63, 287-301.
21. Gong CX, Liu F, Wu G, Rossie S, Wegiel J, Li L, Grundke-Iqbal I, Iqbal K (2004) Dephosphorylation ofmicrotubule-associated protein tau by protein phosphatase5. J Neurochem 88, 298-310.
22. Lee G, Leugers CJ (2012) Tau and tauopathies. Prog Mol Biol Transl Sci 107, 263-293.
23. Avila J, de Barreda EG, Fuster-Matanzo A, Simón D, Llorens-Martn M, Engel T, Lucas JJ, Dáz-Hernández M, Hernández F (2012) Looking for novel functions of tau. Biochem Soc Trans 40, 653-635.
24. Hernández F, Avila J (2008) Tau aggregates and tau pathology. J Alzheimers Dis 14, 449-452.
25. Avila J, Lucas JJ, Perez M, Hernandez F (2004) Role of tauprotein in both physiological and pathological conditions. Physiol Rev 84, 361-384.
26. Blair J, Siedlak S, Wolfram J, Nunomura A, Castellani R, Ferreira S, Klein W, Wang Y, Casadesus G, Smith M, Perry G, Zhu X, Lee H (2014) Accumulation of intraneuronalamyloid-is common in normal brain. Curr Alzheimer Res11, 317-324.
27. Bueé L, Bussière T, Bueé-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and rolein neurodegenerative disorders. Brain Res Rev 33, 95-130.
28. Andreadis A (2005) Tau gene alternative splicing: Expressionpatterns, regulation and modulation of function innormal brain and neurodegenerative diseases. Biochim BiophysActa 1739, 91-103.
29. Andreadis A (2012) Tau splicing and the intricacies of dementia. J Cell Physiol 227, 1220-1225.
30. Lee VM, Goedert M, Trojanowski JQ (2001) Neuro degenerative tauopathies. Annu Rev Neurosci 24, 1121-1159.
31. Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K (2004) Promotion of hyper phosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279, 34873-34881.
32. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tausuppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
33. Han D, Qureshi HY, Lu Y, Paudel HK (2009) Familial FTDP-17 missense mutations inhibit microtubule assembly promoting activity of tau by increasing phosphorylation atSer202 in vitro. J Biol Chem 284, 13422-13433.
34. Ferrer Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó1 E, Avila J (2005) Current advances on different kinasesinvolved in tau phosphorylation, and implications inAlzheimer's disease and tauopathies. Curr Alzheimer Res2, 3-18.
35. Gotz J, Chen F, Van Drope J, Nitsch RM (2001) Formation ofneurofibrillary tangles in P301L tau transgenic mice inducedby A-42 fibrils. Science 293, 1491-1495.
36. Johnson GV, Stoothoff WH (2004) Tau phosphorylation inneuronal cell function and dysfunction. J Cell Sci 117, 5721-5729.
37. Maltsev AV, Santockyte R, Bystryak S, Galzitskaya OV (2014) Activation of neuronal defense mechanisms inresponse to pathogenic factors triggering induction of amyloidosisin Alzheimer's disease. J Alzheimers Dis 40, 19-32.
38. Cai Z, Zhao Y, Zhao B (2012) Roles of glycogen synthasekinase 3 in Alzheimer's disease. Curr Alzheimer Res 9, 864-879.
39. Hashiguchi M, Sobue K, Paudel HK (2000) 14-3-3zeta is aneffector of tau protein phosphorylation. J Biol Chem 275, 25247-25254.
40. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tauhyperphosphorylation and neurodegeneration in GSK-3betaconditional transgenic mice. EMBO J 20, 27-39.
41. Shiurba RA, Ishiguro K, Takahashi M, Sato K, Spooner ET, Mercken M, Yoshida R, Wheelock TR, Yanagawa H, Imahori K, Nixon RA (1996) Immunocytochemistry of tauphosphoserine 413 and tau protein kinase I in Alzheimerpathology. Brain Res 737, 119-132.
42. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010-1019.
43. Andreásson C, Fiaux J, Rampelt H, Mayer MP, Bukau B (2008) Hsp110 is a nucleotide-activated exchange factor forHsp70. J Biol Chem 283, 8877-8884.
44. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K (1996) Exposure of rat hippocampalneurons to amyloid beta peptide (25-35) induces theinactivation of phosphatidyl inositol-3 kinase and the activationof tau protein kinase I/glycogen synthase kinase-3beta. Neurosci Lett 203, 33-36.
45. Yang X, Yang Y, Liu J, Li G, Yang E (2012) Increasedphosphorylation of tau and synaptic protein loss in the agedtransgenic mice expressing familiar Alzheimer's diseaselinkedpresenilin 1 mutation. Neurochem Res 37, 15-22.
46. Hiltunen M, Khandelwal VK, Yaluri N, Tiilikainen T, Tusa M, Koivisto H, Krzisch M, Vepsälaïnen S, Mäkinen P, Kemppainen S, Miettinen P, Haapasalo A, Soininen H, Laakso M, Tanila H (2012) Contribution of geneticand dietary insulin resistance to Alzheimer phenotype inAPP/PS1 transgenic mice. J Cell Mol Med 16, 1206-1222.
47. Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B (1998) Presenilin 1 associates withglycogen synthase kinase-3beta and its substrate tau. ProcNatl Acad Sci USA 95, 9637-9641.
48. Pérez M, Hernández F, Lim F, Diáz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau proteinaggregation in a transgenic mouse model. J Alzheimers Dis5, 301-308.
49. Hernandez F, Lucas JJ, Avila J (2013) GSK3 and tau: Twoconvergence points in Alzheimer's disease. J Alzheimers Dis33, 141-144.
50. Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2002) Involvementof aberrant glycosylation in phosphorylation of tau bycdk5 and GSK-3beta. FEBS Lett 530, 209-214.
51. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL, 3rd (2004) Altered expression levels ofthe protein phosphatase 2A ABalphaC enzyme are associatedwith Alzheimer disease pathology. J Neuropathol Exp Neurol 63, 287-301.
52. Shelton SB, Johnson GV (2004) Cyclin-dependent kinase-5in neuro degeneration. J Neurochem 88, 1313-1326.
53. Takahashi S, Saito T, Hisanaga S, Pant HC, Kulkarni AB (2003) Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for micro tubules. J Biol Chem 278, 10506-10515.
54. Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST (2004) A novelCDK5-dependent pathway for regulating GSK3 activityand kinesin-driven motility in neurons. EMBO J 23, 2235-2245.
55. Nishimura I, Yang Y, Lu B (2004) PAR-1 kinase plays an initiatorrole in a temporally ordered phosphorylation processthat confers tau toxicity in Drosophila. Cell 116, 671-682.
56. Fath T, Eidenmüller J, Brandt R (2002) Tau-mediated cytotoxicity in a pseudo hyper phosphorylation model ofAlzheimer's disease. J Neurosci 22, 9733-9741.
57. Wang X, Luebbe P, Gruenstein E, Zemlan F (1998) Apolipoprotein E (ApoE) peptide regulates tau phosphorylationvia two different signaling pathways. J Neurosci Res51, 658-665.
58. Ohkubo N, Lee YD, Morishima A, Terashima T, Kikkawa S, Tohyama M, Sakanaka M, Tanaka J, Maeda N, Vitek MP, Mitsuda N (2003) Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. FASEB J 17, 295-297.
59. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E (1997) MA RK, a novel family of protein kinases that phosphory late micro tubule-associated proteins and trigger micro tubule disruption. Cell 89, 297-308.
60. Chin JY, Knowles RB, Schneider A, Drewes G, Mandelkow EM, Hyman BT, Cho JH, Johnson GV (2004) Glycogen synthasekinase 3 beta induces caspase-cleaved tau aggregationin situ. J Biol Chem 279, 54716-54723.
61. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ (2012) AGEs induce Alzheimer-like tau pathology and memorydeficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 33, 1400-1410.
62. Wang JZ, Grundke-Iqbal I, Iqbal K (1996) Glycosylation of microtubule-associated protein tau: An abnormal post translational modification in Alzheimer's disease. Nat Med2, 871-875.
63. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX (2006) PKA modulates GSK-3beta-andcdk5-catalyzed phosphorylation of tau in site-and kinase specific manners. FEBS Lett 580, 6269-6274.
64. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau:A mechanism involved in Alzheimer's disease. Proc NatlAcad Sci USA 101, 10804-10809.
65. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice inducedby Abeta 42 fibrils. Science 293, 1491-1495.
66. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K (2006) Impairedbrain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J Alzheimers Dis 9, 1-12.
67. Graham DL, Gray AJ, Joyce JA, Yu D, O'Moore J, Carlson GA, Shearman MS, Dellovade TL, Hering H (2013) Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse modelof tauopathy. Neuropharmacology 79, 307-313.
68. Schedin-Weiss S, Winblad B, Tjernberg LO (2014) The roleof protein glycosylation in Alzheimer disease. FEBS J 281, 46-62.
69. Giannopoulos PF, Joshi YB, Praticò D (2014) Novel lipidsignaling pathways in Alzheimer's disease pathogenesis. Biochem Pharmacol 88, 560-564.
70. Tyagi E, Fiorelli T, Norden M, Padmanabhan J (2013) Alpha1-antichymotrypsin, an inflammatory protein overexpressedin the brains of patients with Alzheimer's disease, inducestau hyper phosphorylation through c-Jun N-Terminal kinase activation. Int J Alzheimers Dis 2013, 606083.
71. Conde R, Xavier J, McLoughlin C, Chinkers M, Ovsenek N (2005) Protein phosphatase 5 is a negative modulator of heat shock factor 1. J Biol Chem 280, 28989-28996.
72. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau ubiquitination, degradationand aggregation. Hum Mol Genet 13, 703-714.
73. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G (2007) Rolesof heat-shock protein 90 in maintaining and facilitatingthe neurodegenerative phenotype in tauopathies. Proc NatlAcad Sci USA 104, 9511-9516.
74. Jinwal UK, Trotter JH, Abisambra JF, Koren J 3rd, Lawson LY, Vestal GD, O'Leary JC 3rd, Johnson AG, Jin Y, Jones JR, Li Q, Weeber EJ, Dickey CA (2011) The Hsp90 kinase cochaperoneCdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem 286, 16976-16983.
75. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Viñals F, Ribalta T (2001) Phosphorylatedmap kinase (ERK1, ERK2) expression is associatedwith early tau deposition in neurones and glial cells, but notwith increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11, 144-158.
76. Li J, Deng J, Sheng W, Zuo Z (2012) Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptinresistant mice. Pharmacol Biochem Behav 101, 564-574.
77. Savage MJ, Lin YG, Ciallella JR, Flood DJ, Scott RW (2002) Activation of c-Jun N-terminal kinase and p38 inan Alzheimers disease model is associated with amyloid deposition. J Neurosci 22, 3376-3385.
78. Singh TJ, Zaidi T, Grundke Iqbal, Iqbal K (1996) Nonprolinedependent protein kinase phosphorylate several sitesfound in tau from Alzheimer disease. Mol Cell Biochem 154, 143-151.
79. Pheil CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3-regulates production of Alzheimer's disease amyloid-peptides. Nature 423, 435-439.
80. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthasekinase-3-(GSK-3-) in brains staged for Alzheimersdisease neurofibrillary changes. J Neuropathol Exp Neurol58, 1010-1019.
81. Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M, Sunnemark D, von Euler G (2014) Acta neuropatholcommun MARK4 and MARK3 associate with early tauphosphorylation in Alzheimer's disease granulovacuolar degeneration bodies. Acta Neuropathol Commun 2, 22.
82. Qureshi HY, Han D, MacDonald R, Paudel HK (2013) Overexpression of 14-3-3z promotes tau phosphorylation atSer262 and accelerates proteosomal degradation of synaptophysinin rat primary hippocampal neurons. PLoS One 8, e84615.
83. Drewes G, Ebneth A, Preuss U, Mandelkow EM, MandelkowE (1997) MA RK, a novel family of protein kinasesthat phosphorylate microtubule-associated proteins and triggermicrotubule disruption. Cell 89, 297-308.
84. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulatesCdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
85. Maccioni RBJ, Otth C, Concha II, Muñoz JP (2001) The proteinkinase Cdk5. Structural aspects, roles in neurogenesisand involvement in Alzheimer's pathology. Eur J Biochem268, 1518-1527.
86. Martin SG, St Johnston D (2003) A role for DrosophilaLKB1 in anterior-posterior axis formation and epithelialpolarity. Nature 421, 379-384.
87. Wang JW, Imai Y, Lu B (2007) Activation of PAR-1 kinaseand stimulation of tau phosphorylation by diverse signalsrequire the tumor suppressor protein LKB1. J Neurosci 27, 574-581.
88. Billingsley ML, Kincaid RL (1997) Regulated phosphorylationand dephosphorylation of tau protein: Effects onmicrotubule in teraction, intracellular trafficking and neurodegeneration. Biochem J 323, 577-591.
89. Singh TJ, Grundke-Iqbal I, Iqbal K (1995) Detection ofphosphorylated Ser262 in fetal tau, adult tau, and pairedhelical filament tau in neurodegenerative disorders. J Neurochem64, 1420-1423.
90. Allende JE, Allende CC (1995) Protein kinases 4. Proteinkinase CK2: An enzyme with multiple substrates and a puzzling regulation. FASEB J 9, 313-323.
91. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributionsof protein phosphatases PP1, PP2 A, PP2B and PP5to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
92. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer'sdisease mouse models. Cell 142, 387-397.
93. Hardy J, Selkoe DJ (2002) The amyloid hypothesis ofAlzheimer's disease: Progress and problems on the road totherapeutics. Science 297, 353-356.
94. Thies E, Mandelkow EM (2007) Missorting of tau inneurons causes degeneration of synapses that can berescued by the kinase MARK2/Par-1. J Neurosci 27, 2896-2907.
95. Cai Z, Yan LJ, Li K, Quazi SH, Zhao B (2012) Roles of AMP-activated protein kinase in Alzheimer's disease. Neuromolecular Med 14, 1-14.
96. Chang KH, de Pablo Y, Lee HP, Lee HG, Smith MA, Shah K (2010) Cdk5 is a major regulator of p38 cascade: Relevanceto neurotoxicity in Alzheimer's disease. J Neurochem 113, 1221-1229.
97. Rebeck GW, Hoe HS, Moussa CE (2010) Beta-amyloid1-42gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem 285, 7440-7446.
98. Pehar M, Ko MH, Li M, Scrable H, Puglielli L (2013) P44, the longevity-assurance isoform of P53, regulatestau phosphorylation and is activated in an age-dependent fashion. Aging Cell 13, 449-456.
99. Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca2+ elevation, missortingof endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30, 11938-11950.
100. Flaherty D, Lu Q, Soria J, Wood JG (1999) Regulation of tauphosphorylation in microtubule fractions by apolipoproteinE. J Neurosci Res 56, 271-4.
101. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Köhler A, Glossmann H, Schneider R, Sutherland C, Schweiger S (2010) Biguanidemet form in acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad SciUSA 107, 21830-21835.
102. Augustinack JC, Schneider A, Mandelkow EM, HymanBT (2002) Specific tau phosphorylation sites correlate withseverity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103, 26-35.
103. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, MiyakawaT (1996) Sequential changes of tau-site-specific phosphorylationduring development of paired helical filaments. Dementia 7, 177-181.
104. Jicha GA, Berenfeld B, Davies P (1999) Sequence requirementsfor formation of conformational variants of tau similarto those found in Alzheimer's disease. J Neurosci Res 55, 713-723.
105. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K (2006) Polymerization of hyperphosphorylated tau into filamentseliminates its inhibitory activity. Proc Natl Acad Sci USA 103, 8864-8869.
106. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS (2005) Axonopathy and transport deficits earlyin the pathogenesis of Alzheimer's disease. Science 307, 1282-1288.
107. Stamer K, Vogel R, Thies E, Mandelkow E, MandelkowEM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156, 1051-1063.
108. Ren QG, Liao XM, Chen XQ, Liu GP, Wang JZ (2007) Effects of tau phosphorylation on proteasome activity. FEBS Lett 58, 1521-1528.
109. Trojanowski JQ, Lee VM (2005) Pathological tau: A loss of normal function or a gain in toxicity? Nat Neurosci 8, 1136-1137.
110. Utton MA, Noble WJ, Hill JE, Anderton BH, Hanger DP (2005) Molecular motors implicated in the axonal transportof tau and alpha-synuclein. J Cell Sci 118, 4645-4654.
111. Dubey M, Chaudhury P, Kabiru H, Shea TB (2008) Tauinhibits anterograde axonal transport and perturbs stabilityin growing axonal neurites in part by displacing kinesincargo: Neurofilaments attenuate tau-mediated neurite instability. Cell Motil Cytoskeleton 65, 89-99.
112. Cuchillo-Ibanez I, Seereeram A, Byers HL, Leung KY, Ward MA, Anderton BH, Hanger DP (2008) Phosphorylation oftau regulates its axonal transport by controlling its bindingto kinesin. FASEB J 22, 3186-3195.
113. Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4, 13.
114. Planel E, Krishnamurthy P, Miyasaka T, Liu L, Herman M, Kumar A, Bretteville A, Figueroa HY, Yu WH, Whittington RA, Davies P, Takashima A, Nixon RA, Duff KE (2008) Anesthesia-induced hyperphosphorylation detaches3-repeat tau from microtubules without affecting their stabilityin vivo. J Neurosci 28, 12798-12807.
115. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM (2011) Tauinduceddefects in synaptic plasticity, learning, and memoryare reversible in transgenic mice after switching off the toxictau mutant. J Neurosci 31, 2511-2525.
116. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L (2007) The high-affinity HSP90-CHIP complexrecognizes and selectively degrades phosphorylated tauclient proteins. J Clin Invest 117, 648-658.
117. Samali A, Orrenius S (1998) Heat shock proteins: Regulatorsof stress response and apoptosis. Cell Stress Chaperones3, 228-236.
118. Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp 90 molecular chaperone machinery. Annu Rev Biochem 75, 271-294.
119. Dezwaan DC, Freeman BC (2008) HSP90: The Rosettastone for cellular protein dynamics? Cell Cycle 7, 1006-1012.
120. Johnson JL, Brown C (2009) Plasticity of the Hsp90 chaperonemachine in divergent eukaryotic organisms. Cell StressChaperones 14, 83-94.
121. Goryunov D, Liem RK (2007) CHIP-ping away at tau. J ClinInvest 117, 590-592.
122. Riedel M, Goldbaum O, Schwarz L, Schmitt S, Richter-Landsberg C (2010) 17-AAG induces cytoplasmic alphasynucleinaggregate clearance by induction of autophagy. PLoS One 5, e8753.
123. Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, Murata S, Tanaka K, Takashima A (2005) Invivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 94, 1254-1263.
124. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Höhfeld J, Patterson C (2001) The co-chaperone CHIPregulates protein triage decisions mediated by heat-shockproteins. Nat Cell Biol 3, 93-96.
125. Murata S, Minami Y, Minami M, Chiba T, Tanaka K (2001) CHIP is a chaperone-dependent E3 ligase that ubiquitylatesunfolded protein. EMBO Rep 2, 1133-1138.
126. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R (1998) Repression of heat shock transcription factor HSF1activation by HSP90 (HSP90 complex) that forms a stresssensitivecomplex with HSF1. Cell 94, 471-480.
127. Shimura H, Schwartz D, Gygi SP, Kosik KS (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau andenhances cell survival. J Biol Chem 279, 4869-4876.
128. Shimura H, Schwartz D, Gygi SP, Kosik KS (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau andenhances cell survival. J Biol Chem 279, 4869-4876.
129. Kumar P, Pradhan K, Karunya R, Ambasta RK, QuerfurthHW (2012) Cross-functional E3 ligases parkin andC-terminus Hsp-70 interacting protein in neurodegenerativedisorders. J Neurochem 120, 350-370.
130. Qian SB, McDonough H, Boellmann F, Cyr DM, Patterson C (2006) CHIP-mediated stress recovery by sequentialubiquitination of substrates and Hsp70. Nature 440, 551-555.
131. Magrané J, Smith RC, Walsh K, QuerfurthHW (2004) Heatshock protein 70 participates in the neuroprotective responseto intracellularly expressed beta-amyloid in neurons. J Neurosci24, 1700-1706.
132. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C, Patterson C, Hutton M, PetrucelliL (2006) Deletion of the ubiquitin ligase CHIP leads to theaccumulation, but not the aggregation, of both endogenousphospho-and caspase-3-cleaved tau species. J Neurosci 26, 6985-6996.
133. Hatakeyama S, Matsumoto M, Kamura T, Murayama M, Chui DH, Planel E, Takahashi R, Nakayama KI, TakashimaA (2004) U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylationpreferentially on four-repeat tau and is involved in neurodegenerationof tauopathy. J Neurochem 91, 299-307.
134. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, YangAJ (2006) Alzheimer disease-specific conformation ofhyperphosphorylated paired helical filament-tau is polyubiquitinatedthrough Lys-48, Lys-11, and Lys-6 ubiquitinconjugation. J Biol Chem 281, 10825-10838.
135. Dragovic Z, Broadley SA, Shomura Y, Bracher A, Hartl FU (2006) Molecular chaperones of the Hsp110 family act asnucleotide exchange factors of Hsp70s. EMBO J 25, 2519-2528.
136. Eroglu B, Moskophidis D, Mivechi NF (2010) Loss ofHsp110 leads to age-dependent tau hyperphosphorylationand early accumulation of insoluble amyloid beta. Mol CellBiol 30, 4626-4643.
137. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L (2008) Akt and CHIP coregulate tau degradation throughcoordinated interactions. Proc Natl Acad Sci USA 105, 3622-3627.
138. Shimura H, Miura-Shimura Y, Kosik KS (2004) Binding of tau to heat shock protein 27 leads to decreased concentrationof hyper phosphorylated tau and enhanced cell survival. J Biol Chem 279, 17957-17962.
139. Abisambra JF, Blair LJ, Hill SE, Jones JR, Kraft C, Rogers J, Koren J 3rd, Jinwal UK, Lawson L, Johnson AG, Wilcock D, O'Leary JC, Jansen-West K, Muschol M, Golde TE, Weeber EJ, Banko J, Dickey CA (2010) Phosphorylation dynamicsregulate Hsp27-mediated rescue of neuronal plasticitydeficits in tau transgenic mice. J Neurosci 30, 15374-15382.
140. Xi JH, Bai F, McGaha R, Andley UP (2006) Alpha-crystallin expression affects microtubule assembly and prevents their aggregation. FASEB J 20, 846-857.
141. Dabir DV, Trojanowski JQ, Richter-Landsberg C, Lee VM, Forman MS (2004) Expression of the small heat-shock proteinalphaB-crystallin in tauopathies with glial pathology. Am J Pathol 164, 155-166.
142. Van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koÿcü S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM (1998) Frameshift mutants of beta amyloidprecursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279, 242-247.
143. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP (2002) Mutant ubiquitin found in neurodegenerative disorders is aubiquitin fusion degradation substrate that blocks proteasomaldegradation. J Cell Biol 157, 417-427.
144. Hope AD, de Silva R, Fischer DF, Hol EM, van Leeuwen FW, Lees AJ (2003) Alzheimer's associated variant ubiquitincauses inhibition of the 26S proteasome and chaperoneexpression. J Neurochem 86, 394-404.
145. Nixon RA, Cataldo AM, Mathews PM (2000) Theendosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: Areview. Neurochem Res 25, 1161-1172.
146. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG (2002) Proteasomal degradation of tau protein. J Neurochem 83, 176-185.
147. Babu JR, Geetha T, Wooten MW (2005) Sequestosome1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94, 192-203.
148. Zhang JY, Liu SJ, Li HL, Wang JZ (2005) Microtubuleassociatedprotein tau is a substrate of ATP/Mg (2+)-dependent proteasome protease system. J Neural Transm 112, 547-555.
149. Poppek D, Keck S, Ermak G, Jung T, Stolzing A, Ullrich O, Davies KJ, Grune T (2006) Phosphorylation inhibitsturnover of the tau protein by the proteasome: Influence of RCAN1 and oxidative stress. Biochem J 400, 511-520.
150. Elliott E, Tsvetkov P, Ginzburg I (2007) BAG-1 associateswith Hsc70-tau complex and regulates the proteasomaldegradation of tau protein. J Biol Chem 282, 37276-37284.
151. Yoon SY, Choi JE, Kweon HS, Choe H, Kim SW, Hwang O, Lee H, Lee JY, Kim DH (2008) Okadaic acidincreases autophagosomes in rat neurons: Implications for Alzheimer's disease. J Neurosci Res 86, 3230-3239.
152. Cho JH, Johnson GV (2004) Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem 279, 54716-54723.
153. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S (2004) GSK-3 beta inhibitionreverses axonal transport defects and behaviouralphenotypes in Drosophila. Mol Psychiatry 9, 522-530.
154. Hamano T, Yen SH, Gendron T, Ko LW, Kuriyama M (2012) Pitavastatin decreases tau levels via the inactivationof Rho/ROCK. Neurobiol Aging 33, 2306-2320.
155. Ma SL, Pastorino L, Zhou XZ, Lu KP (2012) Prolylisomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3-(GSK3-) activity: Novel mechanism for Pin1 toprotect against Alzheimer disease. J Biol Chem 287, 6969-6973.
156. Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK (2004) PS1 activates PI3 Kthus inhibiting GSK-3 activity and tau overphosphorylation:Effects of FAD mutations. EMBO J 23, 2586-2596.
157. Zheng YL, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC (2005) Acdk 5 inhibitory peptide reduces tau hyperphosphorylationand apoptosis in neurons. EMBO J 24, 209-220.
158. Ono K, Yamada M (2012) Vitamin A and Alzheimer's disease. Geriatr Gerontol Int 12, 180-188.
159. Murakami K, Murata N, Ozawa Y, Kinoshita N, Irie K, Shirasawa T, Shimizu T (2011) Vitamin C restores behavioraldeficits and amyloid-oligomerization without affectingplaque formation in a mouse model of Alzheimer's disease. J Alzheimers Dis 26, 7-18.
160. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributionsof protein phosphatases PP1, PP2 A, PP2B and PP5to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
161. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J (1999) Direct binding of Reelin to VLDL receptor and ApoE receptor 2 inducestyrosine phosphorylation of disabled-1 and modulates tauphosphorylation. Neuron 24, 481-489.
162. Song MS, Rauw G, Baker GB, Kar S (2008) Memantineprotects rat cortical cultured neurons against beta-amyloidinducedtoxi city by attenuating tau phosphorylation. Eur J Neuro sci 28, 1989-2002.
163. Luo W, Sun W, Taldone T, Rodina A, Chiosis G (2010) Heat shock protein 90 in neurodegenerative diseases. MolNeurodegener 5, 24.
164. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domainof heat shock protein 90 (hsp90) that binds geldanamycinis an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272, 23843-23850.
165. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperonesincrease association of tau protein with microtubules. ProcNatl Acad Sci USA 100, 721-726.
166. Dou F, Chang X, Ma D (2007) Hsp90 maintains the stabilityand function of the tau phosphorylating kinase GSK3. Int J Mol Sci 8, 51-60.
167. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L (2006) HSP induction mediates selective clearance of tau phosphorylate dat proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20, 753-755.
168. Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, Paudel HK (2002) Glycogen synthasekinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem 277, 11933-11940.
169. Cho JH, Johnson GV (2004) Primed phosphorylation of tauat Thr 231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind andstabilize microtubules. J Neurochem 88, 349-358.
170. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L (2007) An acetylation site in the middledomain of Hsp90 regulates chaperone function. Mol Cell 25, 151-159.
171. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heatshock protein 90: A novel basis for antileukemia activityof histone deacetylase inhibitors. J Biol Chem 280, 26729-26734.
172. Dai Q, Zhang C, Wu Y, McDonough H, Whaley RA, Godfrey V, Li HH, Madamanchi N, Xu W, Neckers L, Cyr D, Patterson C (2003) CHIP activates HSF1 and confers protectionagainst apoptosis and cellular stress. EMBO J 22, 5446-5458.
173. Jinwal UK, Koren J, O'Leary JC, Jones JR, Abisambra JF, Dickey CA (2010) Hsp70 ATPase modulators as therapeuticsfor Alzheimer's and other neurodegenerative diseases. Mol Cell Pharmacol 2, 43-46.
174. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A (2012) Immunotherapy for Alzheimer's disease: Fromanti-amyloid to tau-based immunization strategies. Immunotherapy 4, 213-238.
175. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA (2013) Curcumin suppresses soluble tau dimers and correctsmolecular chaperone, synaptic, and behavioral deficitsin aged human tau transgenic mice. J Biol Chem 288, 4056-4065.
176. Garcá-Osta A, Cuadrado-Tejedor M, Garciá-Barroso C, Oyarzábal J, Franco R (2012) Phosphodiesterases as therapeutictargets for Alzheimer's disease. ACS Chem Neurosci 3, 832-844.
177. Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, Studahl M, GisslénM (2013) Cerebrospinal fluidAlzheimer's biomarker profiles in CNS infections. J Neurol260, 620-626.
178. Prikrylová Vranová H, Mares J, Hlustk P, Nevrlý M, Stejskal D, Zapletalová J, Obereigneru R, Kanovský P (2012) Tau protein and beta-amyloid (1-0 42) CSF levels in differentphenotypes of Parkinson's disease. J Neural Transm 119, 353-362.
179. Chen LM, Xiong YS, Kong FL, Qu M, Wang Q, Chen XQ, Wang JZ, Zhu LQ (2012) Neuroglobin attenuatesAlzheimer-like tau hyperphosphorylation by activating Aktsignaling. J Neurochem 120, 157-164.
180. Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, LiuYZ (2012) (Val8) glucagon-like peptide-1 prevents tauhyperphosphorylation, impairment of spatial learning andultra-structural cellular damage induced by streptozotocinin rat brains. Eur J Pharmacol 674, 280-286.
181. Zhou F, Chen S, Xiong J, Li Y, Qu L (2012) Luteolin reduceszinc-induced tau phosphorylation at Ser262/356 in an ROSdependentmanner in SH-SY5Y cells. Biol Trace Elem Res149, 273-279.
182. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) BlockingIL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal-catenin pathway function in anAlzheimer's disease model. J Immunol 187, 6539-6549.
183. Luna-Muñoz J, Chávez-Macás L, Garcá-Sierra F, Mena R (2007) Earliest stages of tau conformational changesare related to the appearance of a sequence of specificphospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis 12, 365-375.
184. Davidowitz EJ, Chatterjee I, Moe JG (2008) Targeting tauoligomers for therapeutic development for Alzheimer's diseaseand tauopathies. Curr Topics Biotechnol 4, 47-64.
185. Kontsekova E, Ivanovova N, Handzusova M, Novak M (2009) Chaperone-like antibodies in neurodegenerativetauopathies: Implication for immunotherapy. Cell Mol Neurobiol29, 793-798.
186. Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H (2011) Hsp90 regulates tau pathology through co-chaperonecomplexes in Alzheimer's disease. Prog Neurobiol 93, 99-110.
187. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC (2009) Rapamycin and m TOR-independent autophagy inducersameliorate toxicity of polyglutamine-expanded huntingtinand related proteinopathies. Cell Death Differ 16, 46-56.
188. Veereshwarayya V, Kumar P, Rosen KM, Mestril R, QuerfurthHW (2006) Differential effects of mitochondrial heatshock protein 60 and related molecular chaperones to preventintracellular amyloid-induced inhibition of complex IVand limit apoptosis. J Biol Chem 281, 29468-29478.
189. Kumar P, Ambasta RK, Veereshwarayya V, Rosen KM, Kosik KS, Band H, Mestril R, Patterson C, QuerfurthHW (2007) CHIP and HSPs interact with beta-APPin a proteasome-dependent manner and influence Abetametabolism. Hum Mol Genet 16, 848-864.
190. Evans CG, Wisen S, Gestwicki JE (2006) Heat shock proteins70 and 90 inhibit early stages of amyloid-(1-42) aggregation in vitro. J Biol Chem 281, 33182-33191.
191. Dedmon MM, Christodoulou J, Wilson MR, Dobson CM (2005) Heat shock protein 70 inhibits alpha-synuclein fibrilformation via preferential binding to prefibrillar species. J Biol Chem 280, 14733-14740.
192. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU (2000) Hsp70 and hsp40 chaperonescan inhibit self-assembly of polyglutamine proteins intoamyloid-like fibrils. Proc Natl Acad Sci USA 97, 7841-7846.
193. Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G (2005) Pharmacologicalinduction of heat-shock proteins alleviates polyglutaminemediatedmotor neuron disease. Proc Natl Acad Sci USA102, 1606-1680.
194. Kalmar B, Lu CH, Greensmith L (2014) The role of heatshock proteins in Amyotrophic Lateral Sclerosis: The therapeuticpotential of Arimoclomol. Pharmacol Ther 141, 40-54.
195. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY (1998) Chaperone suppression of aggregationand altered subcellular proteasome localization implyprotein misfolding in SCA1. Nat Genet 19, 148-154.
196. Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, Tanaka K, Nukina N (2005) Co-chaperone CHIP associateswith expanded polyglutamine protein and promotestheir degradation by proteasomes. J Biol Chem 280, 11635-11640.
197. Zijlstra MP, Rujano MA, Van Waarde MA, Vis E, Brunt ER, Kampinga HH (2010) Levels of DNAJB family members (HSP40) correlate with disease onset in patients withspinocerebellar ataxia type 3. Eur J Neurosci 32, 760-770.